Form 4: Gilead Sciences Director Kramer Reports Stock Option and Restricted Stock Unit Grant
SEC Form 4 Filing
Kelly A. Kramer, a director of Gilead Sciences, reported the acquisition of stock options and restricted stock units on May 8, 2024.
Summary
- On May 8, 2024, Kelly A. Kramer, a director of Gilead Sciences, reported transactions involving derivative securities.
- Kramer acquired 12,648 non-qualified stock options with an exercise price of $64.92, exercisable immediately and expiring on May 8, 2034.
- Kramer also acquired 2,310 restricted stock units, which vested immediately and represent the right to receive one share of Gilead Sciences, Inc.'s common stock each.
- Following the reported transactions, Kramer beneficially owns 12,648 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions related to executive compensation. It doesn't inherently indicate positive or negative performance for the company.
Positives
- The immediate vesting of both the stock options and restricted stock units could be seen as a positive incentive for the director.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry.
Comparison to Industry Standards
- Stock option grants and restricted stock units are standard components of executive compensation packages in the pharmaceutical industry, used to align the interests of management with those of shareholders.
- Companies like Amgen, Pfizer, and Johnson & Johnson also utilize similar equity-based compensation strategies.
- The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness.
Stakeholder Impact
- The grant of stock options and restricted stock units aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of the transaction: acquisition of stock options and restricted stock units. |
| 05/08/2024 | Grant date and vesting date for both restricted stock units and stock options. |
| 05/08/2034 | Expiration date for the non-qualified stock options. |
| 05/09/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.